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MaOBJECTIVES The goal of this study was to assess the diffuse myocardial ﬁbrosis and edema in rheumatoid arthritis (RA)
using multiparametric cardiac magnetic resonance (CMR) and the association of myocardial T1 and extracellular volume
(ECV) with disease activity, duration, and cardiac function.
BACKGROUND RA is a connective tissue disorder, with frequent cardiovascular disease. Myocardial inﬂammation and
diffuse ﬁbrosis can be detected noninvasively by using native T1 mapping and ECV quantiﬁcation on CMR.
METHODS Thirty-nine RA patients (28 women; mean age 50  12 years) and 39 matched control subjects (28 women;
mean age 49  12 years) underwent CMR at 1.5-T, including cine, tagging, T2-weighted, native T1 mapping (shortened
modiﬁed Look-Locker inversion recovery), late gadolinium enhancement (LGE), and ECV imaging.
RESULTS Focal ﬁbrosis on LGE was found in 46% of RA patients compared with none of the control subjects. Patients
with RA had larger areas of focal myocardial edema (10% vs. 0%), higher native T1 values (973  27 ms vs. 961  18 ms;
p ¼ 0.03), larger areas of involvement as detected by native T1 >990 ms (35% vs. 2%; p < 0.001), and expansion of ECV
(30.3  3.4% vs. 27.9  2.0%; p < 0.001) compared with control subjects. Left ventricular volumes, mass, and ejection
fraction were similar between RA patients and control subjects. Peak systolic circumferential strain (–16.9  1.3 vs. –18.7
 1.2; p < 0.001) and peak diastolic circumferential strain rate (83  21 s–1 vs. 112  20 s–1; p < 0.001) were impaired in
RA patients. Myocardial T1 and ECV were correlated with myocardial strain and RA disease activity.
CONCLUSIONS Subclinical cardiovascular disease is frequent in RA, including focal and diffuse myocardial ﬁbrosis and
inﬂammation, which are associated with impaired strain and RA disease activity. CMR T1 mapping provides potential
added value as a biomarker for disease monitoring and study of therapies aimed at reducing diffuse myocardial ﬁbrosis in
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AB BR E V I A T I O N S
AND ACRONYM S
CMR = cardiac magnetic
resonance
CRP = C-reactive protein
DAS28-CRP = disease activity
score with 28 tender and
swollen joint count,
incorporating C-reactive
protein
ECV = extracellular volume
LA = long atrial
LGE = late gadolinium
enhancement
LV = left ventricular
MI = myocardial infarction
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527R heumatoid arthritis (RA) is a chronic autoim-mune disease of the joints, associated withpain, swelling, limited mobility, disability,
and premature death (1). RA is commonly associated
with extra-articular features, including cardiovascular
complications (2). Cardiovascular involvement in RA
predominantly affects young female subjects and
accounts for 40% to 80% of the premature
mortality and a consequent 10-year reduction in
life span (3–5). Myocardial disease in RA results
from a combination of processes that includes chronic
inﬂammation, myocardial ﬁbrosis, focal nonspeciﬁc
diffuse necrotizing or granulomatous myocarditis,
microvascular dysfunction, unrecognized myocardial
infarction (MI), and the drugs used in the treatment
of RA (6).SEE PAGE 537
SA = short-axis
SI = signal intensity
STIR = short-tau inversion
recovery
RA = rheumatoid arthritisCardiac magnetic resonance (CMR) has been used
in the comprehensive noninvasive assessment of
myocardial abnormalities in RA (7,8). Late gadolin-
ium enhancement (LGE), representing focal myocar-
dial ﬁbrosis/scarring, reportedly occurs in 39% of RA
patients, likely from earlier myocarditis (7). However,
LGE relies on the comparison of focal myocardial
damage against unaffected normal myocardium and
is thus limited in detecting diffuse myocardial
ﬁbrosis, which often occurs in RA (6). Results of
endomyocardial biopsy may conﬁrm the histologic
detection of myocardial ﬁbrosis (9). Extracellular
volume (ECV) mapping based on measurement of
CMR T1 relaxation times has proved to be a robustFIGURE 1 Strobe Diagram
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Patients with rheumatoid arthritis (RA) screened and included in the stutool for the noninvasive assessment of
diffuse myocardial ﬁbrosis (10,11). T1 map-
ping and ECV estimation correlate well with
histological evidence of myocardial ﬁbrosis
in various clinical contexts (12,13). We there-
fore hypothesized that CMR T1 mapping
would reveal subtle forms of myocardial
inﬂammation and diffuse myocardial ﬁbrosis
in asymptomatic RA patients with no known
cardiovascular involvement compared with
control subjects of similar age and sex.
Furthermore, we sought to investigate the
relation between CMR parameters of diffuse
ﬁbrosis and myocardial inﬂammation and
indexes of RA disease activity and duration.
Finally, we examined the relation between
diffuse myocardial ﬁbrosis and left ventri-
cular (LV) regional systolic and diastolic
function.
METHODSSTUDY POPULATION. This was a prospective study
enrolling nonselected patients with RA (N ¼ 39) with
no known cardiovascular disease. RA patients were
recruited from 4 hospitals in the Thames Valley,
United Kingdom. They underwent clinical assessment
and CMR scanning between November 2010 and
December 2012. Patients with RA included in the
study were between 18 and 65 years of age and had a
conﬁrmed diagnosis of RA based on the 1987 Amer-
ican College of Rheumatology criteria (modiﬁed in
2010) (14), as assessed by clinical consultant Patients Excluded
ith known cardiovascular disease
onary artery disease, heart failure,
iomyopathy, atrial fibrillation)
lder than 65 years of age
oo unwell to travel to research center
t keen to undergo MRI
dy. MRI ¼ magnetic resonance imaging.
TABLE 1
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528rheumatologists. Exclusion criteria included inability
to tolerate CMR, contraindications to CMR, nonsinus
rhythm, known heart disease (previous MI, previous
myocarditis on history, heart failure, arrhythmia on
12-lead electrocardiography, or other chronic cardiac
condition), renal impairment (estimated glomerular
ﬁltration rate <30 ml/min), impaired liver function
(alanine aminotransferase level more than twice the
upper limit of normal), and known hypersensitivity to
gadolinium (Figure 1). Female subjects who were
pregnant, lactating, or planning a pregnancy were
also excluded. Healthy volunteers were matched for
age, sex, and ethnicity (N ¼ 39); they had no cardiac
history, were not on cardiovascular medications, and
had a normal electrocardiography and underwent
CMR as control subjects.
All subjects provided written informed consent to
participate in the study. Ethical approval was grantedBaseline Characteristics of the Study Population
Control Subjects
(N ¼ 39)
RA Patients
(N ¼ 39)
p
Value
hic and clinical
and comorbidity
28 (72) 28 (72) 0.99
49  12 50  12 0.65
nsion 2 (5) 5 (13) 0.24
s 0 (0) 1 (3) —
idemia 5 (13) 6 (15) 0.75
/m2 24  4 26  5 0.13
erapy
exate — 34 (87) —
uine — 25 (64) —
mide — 6 (15) —
azine — 6 (15) —
ab — 2 (5) —
lone — 1 (3) —
— 17 (44) —
P 7 (18) 9 (23) 0.56
tivity and
ty indexes
CRP NA 3.3  1.3 —
/h NA 15 (9–19) —
/l 1 (1–2) 9 (4–13) <0.001
obin 14.0  1.4 13.0  1.2 0.38
crit, % 0.42  0.03 0.40  0.05 0.30
ne, mmol/l NA 74  18 —
of RA, yrs NA 7 (4–11) —
of DMARDs, yrs NA 4 (3–6) —
tive NA 31 (79) —
ositive NA 25 (64) —
(%), mean  SD, or median (interquartile range).
nti–cyclic citrullinated peptide antibodies; BMI ¼ body mass index; DAS28-CRP ¼
arthritis disease activity score with 28 tender and swollen joint count, incorporating
rotein; DMARD ¼ disease-modifying antirheumatic drug; ESR ¼ erythrocyte sedi-
ate; HRT/OCP ¼ hormone replacement therapy/oral contraceptive pill; NA ¼ not
NSAID ¼ nonsteroidal anti-inﬂammatory drug; RA ¼ rheumatoid arthritis;
atoid factor.for all study procedures by the Oxford Research
Ethics Committee.
CMR IMAGE ACQUISITION. CMR studies were per-
formed by using a single 1.5-T magnetic resonance
system (Avanto, Siemens Healthcare, Forchheim,
Germany) according to standard and previously pub-
lished methods. A complete stack of short-axis (SA)
images were obtained during breath-hold and cardiac
gating for cine, pre-contrast (native) T1 mapping,
T2-weighted, and LGE imaging. T1 mapping was per-
formed by using the shortened modiﬁed Look-Locker
inversion recovery sequence, and T2-weighted CMR
was performed with the black-blood short-tau inver-
sion recovery (STIR) sequence. Three SA (basal, mid-
ventricular, and apical) scans and a single long-axis
(horizontal) scan were obtained for tagging. Native
T1 maps and T2-weighted and cine-tagged images
were acquired before administration of gadolinium
contrast. LGE imaging was performed by using a
T1-weighted phase-sensitive inversion recovery se-
quence 8 to 12 min after intravenous administration of
a contrast agent (gadoterate meglumine [Dotarem,
Guerbet LLC, Paris, France]; 0.15 mmol/kg of body
weight). A single mid-ventricular SA slice was ac-
quired for post-contrast T1 maps at 1, 2, 3, 4, 8, 15,
and 20 min after the administration of contrast
(gadoterate meglumine). Typical imaging parameters
for the sequences used were as previously published
(15) and are detailed in the Online Appendix.
CMR IMAGE ANALYSIS. All CMR images and maps
were analyzed ofﬂine and in a blinded fashion.
For cine images, analysis of LV ejection fraction
was performed by using Argus software version VB17
(Siemens Healthcare). LV SA epicardial and endocar-
dial borders were manually contoured at end-diastole
and end-systole. LV end-systolic and end-diastolic
volumes were used to calculate stroke volume and
LV ejection fraction as stroke volume/end-diastolic
volume. LV myocardial mass was calculated by sub-
tracting the endocardial volume from the epicardial
volume, based on earlier knowledge of myocardial
speciﬁc gravity (1.05 g/cm3). Left atrial (LA) diameter
was measured in the LV outﬂow tract (3-chamber)
view.
For tagged cine images, post-processing and
semiautomated analysis was performed by using
Cardiac Image Modeler software (CIMTag2D, Uni-
versity of Auckland, Auckland, New Zealand) by al-
igning a grid to the myocardial tagging planes in
end-diastole. End-systole was determined visually,
and tags were adjusted at each frame through the
cardiac cycle. From the mid-SA slice, peak circum-
ferential systolic strain and peak diastolic strain rate
were derived.
TABLE 2 CMR Findings
Control Subjects
(N ¼ 39)
RA Patients
(N ¼ 39)
p
Value
LVEDV indexed to BSA, ml/m2 78  15 80  16 0.63
LVESV indexed to BSA, ml/m2 24  16 23  9 0.62
LVEF, % 73  5 72  7 0.25
LV mass indexed to BSA, g/m2 52  11 54  12 0.34
LA size, mm 27  5 32  5 <0.001
Mid-SA circumferential strain –18.7  1.2 –16.9  1.3 <0.001
Peak diastolic circumferential strain rate, s–1 112  20 83  21 <0.001
Presence of LGE, % 0 18 (46) —
Volume fraction of LGE >2 SDs, % 0 3.7  0.4 —
Global myocardial T2 SI ratio 1.5  0.1 1.6  0.2 0.70
Volume fraction of edema by T2, % 0 10 (2–18) —
Average myocardial T1, ms 961  18 973  27 0.03
Volume fraction of T1 >990 ms, % 2 (1–8) 35 (19–51) <0.001
Post-contrast T1, ms 468  32 450  40 0.04
ECV, % 27.9  2.0 30.3  3.4 <0.001
Values are n (%), mean  SD, or median (interquartile range).
BSA¼ body surface area; CMR¼ cardiac magnetic resonance; ECV¼ extracellular myocardial volume; LA¼ left
atrium; LGE ¼ late gadolinium enhancement; LV ¼ left ventricular; LVEDV ¼ left ventricular end-diastolic
volume; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end-systolic volume; SA ¼ short-
axis; SI ¼ signal intensity; STIR ¼ short-tau inversion recovery; other abbreviation as in Table 1.
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529For STIR images, semiquantitative analysis was
performed by comparing the LV myocardium in the
SA against adjacent skeletal muscle in the same slice,
veriﬁed on a corresponding steady-state free preces-
sion image. The T2 signal intensity (SI) ratio was
calculated as T2 SImyocardium:skeletal ¼ SImyocardium/
SIskeletal muscle. Myocardial edema was diagnosed
when the myocardial T2 SI ratio was >1.9. Care was
taken to exclude nonsuppressed blood pool signal
due to slow-ﬂow adjacent to the subendocardium and
to avoid using areas with abnormally low signal for
normalization.
LGE images were evaluated qualitatively for the
presence or absence, pattern (e.g., subendocardial,
mid-wall, subepicardial, transmural), and regional
distribution of LGE areas by 3 observers, each with at
least 4 years of CMR experience. The detection of LGE
was made by consensus of all 3 observers. In addition,
focal areas of LGE were deﬁned semiquantitatively as
those with SI $2.0 SDs above the mean SI of normal
myocardium according to MC-ROI software (pro-
grammed by S.K.P. in Interactive Data Language
version 6.1, Exelis Visual Information Solutions,
Boulder, Colorado).
For T1 maps, they were manually contoured by
using in-house software MC-ROI to outline the
endocardium and epicardium. They were then di-
vided into 6 segments per slice by using the anterior
right ventricular–LV insertion point as reference for
comparing segments among sequences.
Consistent with earlier reports on ECV estimation
(10,12), we measured pre-contrast and post-contrast
myocardial and blood T1 values, and the estimation
of ECV and lambda was based on multipoint regres-
sion, incorporating all available pre-contrast and
post-contrast points, to increase the robustness of the
estimates by increasing the number of underlying
data points. ECV was calculated as: (1 – hematocrit).
For calculation of post-contrast T1 values, the post-
contrast T1 map acquired at 20 min was utilized for
ECV calculation.
For areas of myocardial involvement by STIR and
native T1 mapping, the following was used: on dark-
blood T2-weighted images, edema was diagnosed
when myocardial T2 SI was >1.9 times that of remote
skeletal muscle. On T1 maps, acute myocardial injury
was diagnosed when T1 was >990 ms. For all quan-
titative analyses of T2-weighted and T1-mapping im-
ages, only regions of myocardium with a contiguous
area of $40 mm2 above the speciﬁed thresholds were
considered relevant (to reduce the detection of noise
as positive ﬁndings). To calculate the extent of a
subject’s myocardial involvement detected by using
tissue characterization techniques, the percentage ofabnormal myocardium (as deﬁned earlier) was
determined for each segment and then averaged for
that subject (16).
RA DISEASE ACTIVITY AND DURATION. Disease ac-
tivity was assessed by using a disease activity score
that incorporates a 28 tender joint and swollen joint
count in addition to a measure of general health,
together with the serum C-reactive protein level
(DAS28-CRP). An absolute level of disease activity can
be selected as a clinically meaningful goal for thera-
peutic intervention; a value of #3.2 was deﬁned as
the threshold for a low disease activity state and <2.6
as the threshold for remission. CMR biomarkers were
also correlated with disease duration. In keeping with
clinical practice, a cutoff of 2 years was used to
distinguish early RA disease duration from estab-
lished duration.
STATISTICAL ANALYSIS. Normality of data was
tested by using the Kolmogorov-Smirnov test. Nor-
mally distributed data are presented as mean  SD
and nonparametric data as median (interquartile
range); categorical data are presented as number
(percentage). The chi-square test or the Fisher exact
test was used to compare dichotomous data. The
unpaired Student t test (when normally distributed)
or Mann-Whitney U test (for nonparametric data)
was used to compare continuous variables between
RA patients and control subjects, as appropriate.
Segmental data were averaged on a per-subject basis
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tering of segments within each subject. Bivariate
correlations were assessed by using the Pearson’s (R)
or the Spearman’s (RS) coefﬁcient, as appropriate. All
statistical tests were 2-tailed, and a p value <0.05 was
considered statistically signiﬁcant. All analyses were
performed using SPSS version 20 (IBM SPSS Statistics,
IBM Corporation, Armonk, New York).
RESULTS
BASELINE CHARACTERISTICS. The patients with RA
were well matched with the control subjects for age,
sex, and comorbidities (Table 1). A majority of the RA
patients were on methotrexate and chloroquine. MostFIGURE 2 Representative Examples of Pre-Contrast and Post-Contr
(A) Normal control with no late gadolinium enhancement (LGE): pre-cont
27.4%. (B) Rheumatoid arthritis (RA) patient with basal inferior and late
445 ms; ECV, 31.6%. (C) RA patient with multiple, near-circumferential
contrast T1, 415 ms; ECV, 37.9%. Values in graphic indicate myocardialpatients had been diagnosed with RA for a median of
7 years (interquartile range: 4 to 11 years). The median
duration of anti-inﬂammatory treatment was 4 years
(interquartile range: 3 to 6). The mean DAS28-CRP
score was 3.3  1.3, which signiﬁes ongoing disease
activity in most patients.
LV AND RIGHT VENTRICULAR STRUCTURE AND
FUNCTION. There was no signiﬁcant difference in LV
size, mass, or ejection fraction between RA patients
and control subjects (Table 2). However, peak systolic
circumferential strain (–16.9  1.3 vs. –18.7  1.2;
p < 0.001) and diastolic strain rate (83  21 s–1 vs.
112  20 s–1; p < 0.001) at mid-SA were impaired in
RA patients compared with control subjects. In
keeping with diastolic dysfunction, the LA diameterast T1 Maps With Corresponding LGE Images
rast T1, 963 ms; post-contrast T1, 478 ms; extracellular volume (ECV),
ral mid-wall LGE (arrows): pre-contrast T1, 983 ms; post-contrast T1,
, small patches of mid-wall LGE (arrows); native T1, 1,001 ms; post-
T1 values.
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531was larger in RA patients compared with control
subjects (32  5 mm vs. 27  5 mm; p < 0.001).
FOCAL MYOCARDIAL FIBROSIS (LGE IMAGING). As
previously reported by others (7), we found an
increased incidence of LGE in RA patients compared
with control subjects (46% vs. 0%), as shown in
Table 2. The majority of LGE was nonischemic in
nature: 28% of RA patients had patchy mid-wall
enhancement in the basal inferior and lateral walls
(Figure 2); 13% had patchy or linear enhancement
involving the septum; and 5% had evidence of pre-
viously unknown MI. In these 2 patients with previ-
ous MI, subsequent coronary angiography conﬁrmed
epicardial coronary artery disease. Quantitative
analysis of LGE revealed that, overall, RA patients
had a small volume of scarring (3.7  0.4% of total
LV mass).
MYOCARDIAL EDEMA (T2-WEIGHTED CMR). On
conventional dark-blood T2-weighted imaging, there
was no signiﬁcant difference in the overall global
myocardial T2 SI ratio between RA patients and con-
trol subjects (1.6  0.2 vs. 1.5  0.1; p ¼ 0.7). However,
patients with RA had signiﬁcantly more areas of focal
myocardial edema within the left ventricle (median
10% vs. 0% in control subjects; p < 0.001).
DIFFUSE MYOCARDIAL FIBROSIS (T1 MAPPING). Native
T1 mapping and post-contrast T1 mapping were
performed in all patients with RA. The 2 RA patients
with MI were excluded from this analysis. RA pa-
tients had signiﬁcantly higher native shortened
modiﬁed Look-Locker inversion recovery T1 values
(973  27 ms vs. 961  18 ms; p ¼ 0.03) and
expanded ECV (30.3  3.4 vs. 27.9  2.0; p < 0.001)
(Figure 3). Patients with RA had signiﬁcantly largerFIGURE 3 Myocardial Involvement in RA Patients as Detected by T1
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Figures 1 and 2.areas of myocardial involvement detected by using
native T1 mapping (median 35% vs. 2% in control
subjects; p < 0.001). When RA patients were strati-
ﬁed according to the presence of LGE, there was no
signiﬁcant difference in native T1 and ECV values
(Table 3). However, patients with LGE had greater
areas of myocardial involvement on volume fraction
of T1 >990 ms (median 33% vs. 13%; p < 0.001).
When grouped according to duration of RA diag-
nosis, there was no difference in native T1 values
(966  27 vs. 963  36; p ¼ 0.79) and ECV (29.8  3.8
vs. 30.4  4.0; p ¼ 0.59) between RA patients with
disease duration <2 years and those with disease
duration >2 years, respectively. Finally, there were
also no differences in native T1 and ECV when RA
patients were separated according to rheumatoid
factor positivity or the presence of anti–cyclic
citrullinated peptide antibodies.
FUNCTIONAL AND CLINICAL CORRELATES OF
DIFFUSE MYOCARDIAL FIBROSIS. Both native T1
(R ¼ 0.54, p < 0.001) and ECV (R ¼ 0.61, p < 0.001)
were moderately correlated with disease activity.
Native T1 and ECV also correlated with peak systolic
strain (R ¼ 0.46, p ¼ 0.003; and R ¼ 0.52, p ¼ 0.001)
and peak diastolic strain rate (R ¼ –0.44, p < 0.001;
and R ¼ –0.49, p < 0.001), respectively (Figure 4). In
addition, the DAS28-CRP score was associated with
peak systolic strain (R ¼ 0.41, p ¼ 0.01) and peak
diastolic strain rate (R ¼ –0.37, p ¼ 0.02) (Figure 5).
Finally, areas of myocardial injury detected by using
T1 mapping correlated with peak systolic strain
(RS ¼ 0.62, p < 0.001), peak diastolic strain rate (RS ¼
–0.68, p < 0.001), and DAS28-CRP score (RS ¼ 0.44,
p ¼ 0.006), respectively.and ECV Quantiﬁcation Compared With Control Subjects
p < 0.001
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0 ms (third panel) demonstrates a range (from mild to more severe forms) of myocardial
nce intervals. Data refer to RA patients only and not to control subjects. In the box and whisker
rquartile range, and the whiskers refer to the range of value measured. Abbreviations as in
TABLE 3 Measures of Subclinical Myocardial Involvement by T1 Mapping and ECV
in RA Patients With and Without LGE
RA Without LGE
(N ¼ 21)
RA With LGE
(N ¼ 18) p Value
Volume fraction of LGE >2 SDs, % 0 4.2 (0.7) —
Pre-contrast T1 (ms) 972  31 974  22 0.82
Volume fraction of T1 >990 ms, % 13 (3–8) 33 (8–53) <0.001
Post-contrast T1, ms* 440  33 462  45 0.07
ECV, % 30.6  4 30.1  2.9 0.66
STIR T2 ratio 1.6  0.1 1.5  0.1 0.78
Volume fraction of edema (T2 STIR SI >1.9), % 5 (2–13) 8 (2–20) 0.06
Values are mean  SD or median (interquartile range). *At 20 min after gadolinium administration.
Abbreviations as in Tables 1 and 2.
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532DISCUSSION
The principal ﬁnding of the current study is that CMR
detects diffuse and focal myocardial ﬁbrosis, as well
as inﬂammation, in patients with RA. Second, in these
RA patients with no known cardiovascular disease,
indexes of diffuse myocardial ﬁbrosis and inﬂamma-
tion were elevated regardless of the presence of LGE
and correlate with the DAS28-CRP score, a measure of
disease activity in RA as well as with systolic and
diastolic strain. Third, diffuse myocardial ﬁbrosis is
unrelated to RA disease duration and is not associ-
ated with the presence of rheumatoid factor or anti–
cyclic citrullinated peptide antibodies. Our results
indicate that assessment of novel tissue characteris-
tics with T1-mapping CMR can provide novel imaging
biomarkers of disease activity, beyond those pro-
vided by standard techniques such as STIR T2-
weighted and LGE imaging.
Myocardial ﬁbrosis is due to deposition of extra-
cellular matrix proteins, including collagen (17), and
has been shown to be associated with adverse car-
diovascular outcomes (18). Myocardial ﬁbrosis in RA
likely represents the ﬁnal common expression of
microvascular disease, macrovascular coronary artery
disease, and chronic myocardial inﬂammation
(myocarditis and cardiomyopathy) (6). The patho-
physiology of LGE is premised on the combination of
increased volume of distribution for gadolinium-
based contrast agent and prolonged washout related
to the decreased capillary density within the scarred
myocardium (19). The increase in gadolinium con-
centration within ﬁbrotic tissue results in T1 short-
ening, and the ﬁbrotic myocardium appears as bright
SI on inversion recovery images compared with the
dark, nonﬁbrotic myocardium. We found that the
prevalence of focal LGE in RA was 46%, with most
patients having a nonischemic pattern of patchy mid-
wall enhancement. Similarly, a previous studyreported LGE in 7 (39%) of 18 RA patients with no
symptomatic cardiac disease (7). We also documented
2 RA patients with previously undiagnosed MIs.
Although the risk of coronary artery disease is higher
in patients with RA (2,3), RA patients are less likely to
report symptoms of angina and are more likely to
experience silent MIs and sudden cardiac death (5).
LGE CMR is an accurate method for measuring focal
myocardial ﬁbrosis. However, its sensitivity is limited
for the assessment of diffuse myocardial ﬁbrosis,
in which the difference in SI between normal and
ﬁbrotic myocardium may not be a discriminator. T1
mapping, before and after contrast, directly measures
the underlying T1 relaxation times with high spatial
resolution. T1 mapping also allows direct parametric
signal quantiﬁcation on a standardized scale for each
myocardial voxel, and it provides better character-
ization of myocardial tissue composition on a global
and regional level than conventional LGE (19). ECV is
derived from the ratio of T1 change in the blood and
myocardium, taking into account the hematocrit level.
In the absence of MI, inﬁltration, or edema, increases
in ECV quantitatively depict the extent of diffuse
myocardial ﬁbrosis (20). We found increased pre-
contrast T1 values and expanded ECV in RA patients,
indicating the presence of subclinical myocardial dis-
ease. Our group has previously published research on
the use of volume fraction of T1 as a sensitive
biomarker of myocardial involvement in patients with
myocarditis and systemic sclerosis (11,15). Elevation in
the volume fraction of native T1 above a threshold of
990msmay indicate myocardial ﬁbrosis or myocardial
inﬂammation not detected by using standard tech-
niques such as T2-weighted STIR or LGE.
Native T1 and ECV were correlated with abnormal
systolic and diastolic strain parameters in these pa-
tients with RA. Myocardial ﬁbrosis has been linked to
abnormal indexes of myocardial strain (21). The
pathophysiology and sequence of events occurring
before the development of structural heart disease in
RA remain unclear. Others have postulated that
myocardial ﬁbrosis detected by using CMR likely
precedes the development of myocardial relaxation
abnormalities (22). Our study adds to the growing
body of evidence regarding the association between
diffuse myocardial ﬁbrosis and impaired myocardial
strain (in the context of adverse structural remodel-
ing in inﬂammatory heart disease).
We also found that native T1 and ECV correlated
with disease activity in RA. Our data support
the hypothesis that systemic inﬂammatory res-
ponse is critical to development of cardiovascular
complications. Early epidemiological observational
and clinical studies are commensurate with this
FIGURE 4 Correlation Between Myocardial Involvement in RA as Detected by Using T1 Parameters and LV Systolic and Diastolic Strains
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533proposition (23). Elevated DAS28-CRP scores in RA
correlate with elevations in pro-inﬂammatory cyto-
kines, including interleukin-1-alpha, interleukin-1-
beta, interleukin-6, tumor necrosis factor-alpha,
leptin, and vascular endothelial growth factor (24);
these factors play a crucial role in mediating pathophy-
siologically important effector functions within the
cardiovascular system, including up-regulation of
vascular adhesion molecules, oxidization of low-
density lipoprotein cholesterol, increased oxidative
stress, endothelial and microvascular dysfunction,
and promotion of atherothrombosis.STUDY LIMITATIONS. In the current study, we
concentrated on pre-contrast and post-contrast tissue
characteristics in RA. Although native myocardial T1
values and ECV may be increased due to other causes
(e.g., cardiac amyloidosis) (15,25), there was no evi-
dence of myocardial inﬁltration, and none of the RA
patients had an LGE pattern suggestive of MI (the
2 patients with MI were excluded from the analysis).
Hence, we are conﬁdent that the increased native
T1 and ECV reﬂect diffuse myocardial ﬁbrosis and
myocardial inﬂammation. Moreover, we have not
validated T1 and ECV measurements against
FIGURE 5 Correlation Between RA Disease Activity and Myocardial Involvement Detected by Using T1 Parameters and LV Systolic and Diastolic Strains
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534histological assessments; endomyocardial biopsy was
not possible in these asymptomatic patients.
Although T1 mapping can detect both myocardial
edema and ﬁbrosis, the technique is not sufﬁciently
evolved to be able to distinguish the underlying
mechanism behind increased extracellular water.
Myocardial biopsy is the only certain way to distin-
guish these 2 pathological features of the myocar-
dium. However, previous publications have shown
good correlation between CMR indexes of diffuse
myocardial ﬁbrosis and histological ﬁbrosis in other
clinical contexts (12,26). Another limitation of this
study was the lack of serum biomarkers of myocardialinjury, including troponins, CRP, and B-natriuretic
peptides. Finally, we report LA diameter, which is
less accurate compared with LA volume as a measure
of LA size. However, measuring LA volume accurately
with CMR would require a complete stack of SA cines
through the atria; this was not part of our scanning
protocol, which was already long in duration.
We have shown that RA is associated with subclin-
ical myocardial ﬁbrosis. It remains unclear how much
of these observations reﬂect RA disease activity and
progression versus the effect of drugs such as metho-
trexate, which reportedly causes hepatic and pulmo-
nary ﬁbrosis (27,28). Indeed, methotrexate was
PERSPECTIVES
CLINICAL COMPETENCY: Subclinical cardiovascular disease is
frequent in RA, including focal and diffuse myocardial ﬁbrosis
and inﬂammation, which are associated with impaired strain and
RA disease activity. Novel CMR T1-mapping tissue characteriza-
tion provides added value as a promising imaging biomarker for
disease monitoring and the study of therapies aimed at reducing
diffuse myocardial ﬁbrosis in RA.
TRANSLATIONAL OUTLOOK: Future studies are warranted
to elucidate the relationship between myocardial ﬁbrosis and
inﬂammation with myocardial strain. Studies are also needed to
clarify to what extent the earlier observations are due to RA
disease activity and progression versus the effect of RA
therapies.
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535associated with mild liver ﬁbrosis in 1% to 52% of pa-
tients with RA (27). Some studies have shown
that although most methotrexate-induced hepatic
enzyme dysfunction is reversible, many patients who
develop hepatic ﬁbrosis also have other risk factors for
ﬁbrosis, including obesity, excessive alcohol intake,
diabetes mellitus, advanced age, and drug-related
factors such as high total methotrexate dose and long
duration of therapy (29). In humans, methotrexate has
not been shown to cause myocardial ﬁbrosis. In an
animal model of autoimmune myocarditis, metho-
trexate was shown to be anti-inﬂammatory, anti-
ﬁbrotic, and to be associated with signiﬁcant
improvement in ejection fraction (30). These data
would support the observed changes being due to the
disease rather than to the use of methotrexate.
CONCLUSIONS
Our results demonstrate the potential of CMR to
depict diffuse and focal myocardial ﬁbrosis and
inﬂammation in RA patients with apparently normal
hearts, in whom indexes of diffuse myocardial
ﬁbrosis and inﬂammation are elevated regardless of
the presence of LGE and correlate with disease ac-
tivity and impaired systolic and diastolic strain
indexes. Novel CMR T1-mapping tissue character-
ization provides added value as promising imaging
biomarkers for disease monitoring and the study
of therapies aimed at reducing diffuse myocardial
ﬁbrosis in RA. Finally, in the future, CMR including T1
mapping may potentially be useful in RA patients at
different stages of the disease to assess the extent of
myocardial involvement and to delineate myocardial
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